Developments in genomics and biotechnology promise significant improvements in our ability to diagnose and treat disease. As such, the patentability of isolated DNA, diagnostic methods, and related products and processes holds significant implications for health, commerce, and social welfare. For some, the patentability of DNA-related products is a natural extension of long-held patent doctrine and essential to the commercial viability of bringing new diagnostics and therapeutics to market. For others, such patents offend principles of keeping natural products in the public domain and may unduly restrict access to life-saving technologies. This panel will address the vexing questions at the heart of patentable subject matter in the life sciences, particularly in light of recent developments at the Supreme Court. Kevin Emerson Collins, Professor of Law, Washington University School of Law Rebecca Eisenberg, Robert and Barbara Luciano Professor of Law, University of Michigan School of Law Mat Gordon, Director of Intellectual Property, Myriad Genetics, Inc. Peter Lee, Professor, UC Davis School of Law Andrew Serafini, Partner, Fenwick & West